Single and multiple dose study of M136101 in healthy subjects.

A Phase 1,randomized,placebo-controlled,double-blind, single and multiple dose study of M136101 in healthy subjects.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031240458

Enrollment

Registered

2024-11-05

Start date

2024-11-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye with meibomian gland dysfunction/Chalazion

Interventions

M136101 or placebo will be topically applied to the eyelid and eyelid margin as a single dose and twice daily for 7 days

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Males who are 18 to 44 years of age at the time of informed consent.

Exclusion criteria

Exclusion criteria: (1)individuals with a history of or concomitant diseases that are considered inappropriate for participation in a clinical trial, such as serious cardiac, hepatic, pulmonary, renal, or hematological diseases. (2)Individuals with abnormal findings at the administration site. (3)Individuals who are judged to be unsuitable as subject by the principal (sub) investigator.

Design outcomes

Primary

Measure	Time frame
Tolerability, Safety, PK	—

Contacts

Public ContactClinical Trials Information -

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-75-325-3279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026